The role of non-coding RNA (Ribonucleic acid) in the LC-Lung Cancer pathogenesis system

ncRNA in Lung Cancer


  • Muhammad Mazhar Fareed Government College University Faisalabad


Circ-RNA, lncRNA, NonCoding RNA, Lung Cancer


Lung Cancer is a globally alarming deathly disease, the present circumstance is additionally upheld by yearly expansion in new (Lung Cancer) LC-cases and its helpless five years endurance which is under 15%. Albeit an enormous level of LC cases has been credited to smoking, a lot of non-smokers likewise fosters this sickness, accordingly recommending a hereditary as well as epigenetic hint to LC advancement. A few developments related qualities like epidermal development factor receptor (EGFR) and vascular endothelial development factor (VEGF) just as growth silencer qualities, for example, p53 have been involved in LC pathogenesis and movement. Similarly, the genome just holds back around 1% of coding areas. Henceforth, noncoding part of the genome, for example, noncoding RNAs (ncRNAs) has been considered and found to assume a fitting part in LC pathogenesis. All the more exactly, microRNAs (miRNAs) and long ncRNAs (lncRNAs) have been read for quite a long time. Posttranscriptional quality balance capacity of miRNAs is grounded and described. Moreover, the offending communication among lncRNAs and miRNAs had additionally been demonstrated to additional control quality articulation during solid and infection conditions like LC. All the more as of late, restored consideration toward roundabout RNAs circular RNAs (circRNAs) study showed that circRNAs can likewise wipe miRNAs to regulate quality articulations as well. Henceforth, miRNAs, lncRNAs, and circRNAs appear to work inside a circuit to ideally figure out which quality is should have been upregulated or on the other hand downregulated in organic framework. Consequently, this survey will talk about significant ncRNAs, in particular miRNA, lncRNA, and circRNA in LC movement. What's more, the possibility of these ncRNAs in improving better LC treatment will be featured also.


Download data is not yet available.


Batista, P. J., & Chang, H. Y. (2013). Long noncoding RNAs: cellular address codes in development and disease. Cell, 152(6), 1298-1307.

Braicu, C., Zimta, A.-A., Harangus, A., Iurca, I., Irimie, A., Coza, O., & Berindan-Neagoe, I. (2019). The function of non-coding RNAs in lung cancer tumorigenesis. Cancers, 11(5), 605.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.

Conn, S. J., Pillman, K. A., Toubia, J., Conn, V. M., Salmanidis, M., Phillips, C. A., . . . Goodall, G. J. (2015). The RNA binding protein quaking regulates formation of circRNAs. Cell, 160(6), 1125-1134.

Dhanoa, J. K., Sethi, R. S., Verma, R., Arora, J. S., & Mukhopadhyay, C. S. (2018). Long non-coding RNA: its evolutionary relics and biological implications in mammals: a review. Journal of animal science and technology, 60(1), 1-10.

Esteller, M. (2011). Non-coding RNAs in human disease. Nature reviews genetics, 12(12), 861-874.

Hanna, J., Hossain, G. S., & Kocerha, J. (2019). The potential for microRNA therapeutics and clinical research. Frontiers in genetics, 10, 478.

Hashimoto, Y., Akiyama, Y., & Yuasa, Y. (2013). Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PloS one, 8(5), e62589.

He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007). microRNAs join the p53 network—another piece in the tumour-suppression puzzle. Nature Reviews Cancer, 7(11), 819-822.

Hua, Q., Jin, M., Mi, B., Xu, F., Li, T., Zhao, L., . . . Huang, G. (2019). LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. Journal of hematology & oncology, 12(1), 1-18.

Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., & Jacks, T. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences, 105(10), 3903-3908.

Landi, M. T., Consonni, D., Rotunno, M., Bergen, A. W., Goldstein, A. M., Lubin, J. H., . . . Subar, A. F. (2008). Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer. BMC public health, 8(1), 1-10.

Liu, C.-X., Li, X., Nan, F., Jiang, S., Gao, X., Guo, S.-K., . . . Ding, H. (2019). Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell, 177(4), 865-880. e821.

Liu, C., Hu, W., Li, L.-L., Wang, Y.-X., Zhou, Q., Zhang, F., . . . Li, D.-J. (2018). Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncology, 14(27), 2875-2886.

Liu, F., Cai, Y., Rong, X., Chen, J., Zheng, D., Chen, L., . . . Ruan, J. (2017). MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer. Molecular cancer, 16(1), 1-11.

Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016). Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO open, 1(3), e000060.

Naghavi, M., Abajobir, A. A., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abera, S. F., . . . Agrawal, A. (2017). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1151-1210.

Pan, B., Chen, Y., Song, H., Xu, Y., Wang, R., & Chen, L. (2015). Mir-24-3p downregulation contributes to VP16–DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget, 6(1), 317.

Park, S.-Y., Lee, J. H., Ha, M., Nam, J.-W., & Kim, V. N. (2009). miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nature structural & molecular biology, 16(1), 23-29.

Thavaneswaran, S., Rath, E., Tucker, K., Joshua, A. M., Hess, D., Pinese, M., . . . Thomas, D. M. (2019). Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 16(6), 386-396.

Wan, L., Zhang, L., Fan, K., Cheng, Z.-X., Sun, Q.-C., & Wang, J.-J. (2016). Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/β-catenin pathway. BioMed research international, 2016.

Zhong, Y., Wu, X., Li, Q., Ge, X., Wang, F., Wu, P., . . . Miao, L. (2019). Long noncoding RNAs as potential biomarkers and therapeutic targets in gallbladder cancer: a systematic review and meta-analysis. Cancer cell international, 19(1), 1-10.



How to Cite

Fareed, M. M. (2021). The role of non-coding RNA (Ribonucleic acid) in the LC-Lung Cancer pathogenesis system : ncRNA in Lung Cancer. European Journal of Volunteering and Community-Based Projects, 1(4), 49-56. Retrieved from